2Lima A L, Oliveira P R,Paula A P. Acinetobacter infection[J]. N Engl J Med,2008,358(12):1271 -1281.
3Karageorgopoulos D E, Falagas M E. Current control and treatment of muhidrug-resistant Acinetobact er baumannii infections[J]. Lancet Infect Dis,2008,8(12):751 -762.
4Peleg A Y, Seifert H,Paterson D L. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin MicrobioI Rev, 2008, 21(3):538- 582.
5Shih M J, l.ee N Y, 1.ee H C, et al. Risk factors of rnuhidrug resistance in nosocomial bacteremia due to Acinetobacter baumarmii: a case control study[J]. J Microbiol Immunol Infect, 2008,41(2) :118 -123.
6Luna C M, Aruj P K. Nosocomial acinetobacter pneumonia[J]. Respirology, 2007,12 (6) : 787- 791.
7Maragakis I. L, Perl T M. Acinetobacter baumannii: epidemiology, anti microbial resistance, and treatment options [J]. ClinInfect Dis,2008,46(8):1254-1263.
8Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of muhidrug resistant Acinetobacter baumannii infections[J]. J AntimicrobChemother,2008,61(2):117-420.
5Mahgoub S, Ahmed J, Glatta E. Underlying characteristics of pa- tients harbo ring highly resistant Acinetobacter baumannii. Am J Infect Control,2002,30 (7) : 386.
6Naas T, Levy M, Hirschauer C, et al. Outbreak of carbapenem re- sistant A cinetobacter baumannii producing the carbapenem aseOXA223 in a tertiary care hospital of papeete, French Polynesia. J Clin Microbio,2005,43(9) :4826.
